Ken Griffin
ADPT icon

Ken Griffin’s Adaptive Biotechnologies ADPT Stock Holding History

Ken Griffin’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Sell
14,600
-7,200
-33% -$115K ﹤0.01% 11402
2025
Q4 		$354K Buy
21,800
+9,800
+82% +$160K ﹤0.01% 9786
2025
Q3 		$180K Sell
12,000
-6,000
-33% -$73.1K ﹤0.01% 11374
2025
Q2 		$210K Sell
18,000
-9,500
-35% -$86.3K ﹤0.01% 10577
2025
Q1 		$204K Buy
27,500
+20,700
+304% +$159K ﹤0.01% 10407
2024
Q4 		$40.8K Sell
6,800
-30,900
-82% -$170K ﹤0.01% 12603
2024
Q3 		$193K Buy
37,700
+29,300
+349% +$128K ﹤0.01% 10205
2024
Q2 		$30.4K Buy
8,400
+5,800
+223% +$18.4K ﹤0.01% 12259
2024
Q1 		$8.35K Sell
2,600
-36,700
-93% -$142K ﹤0.01% 13562
2023
Q4 		$193K Buy
39,300
+21,900
+126% +$99.9K ﹤0.01% 10014
2023
Q3 		$94.8K Sell
17,400
-4,700
-21% -$31.1K ﹤0.01% 10965
2023
Q2 		$148K Sell
22,100
-7,500
-25% -$55.8K ﹤0.01% 10358
2023
Q1 		$261K Sell
29,600
-15,600
-35% -$138K ﹤0.01% 9669
2022
Q4 		$345K Buy
45,200
+23,000
+104% +$179K ﹤0.01% 9006
2022
Q3 		$158K Sell
22,200
-5,200
-19% -$49K ﹤0.01% 10651
2022
Q2 		$222K Sell
27,400
-17,300
-39% -$152K ﹤0.01% 10475
2022
Q1 		$620K Buy
44,700
+16,500
+59% +$259K ﹤0.01% 8874
2021
Q4 		$791K Sell
28,200
-27,400
-49% -$840K ﹤0.01% 8518
2021
Q3 		$1.89M Sell
55,600
-129,700
-70% -$4.69M ﹤0.01% 6504
2021
Q2 		$7.57M Sell
185,300
-80,400
-30% -$3.13M ﹤0.01% 3593
2021
Q1 		$10.7M Buy
265,700
+191,200
+257% +$10.3M ﹤0.01% 2868
2020
Q4 		$4.41M Buy
74,500
+20,300
+37% +$1.05M ﹤0.01% 3892
2020
Q3 		$2.64M Buy
54,200
+20,000
+58% +$841K ﹤0.01% 4211
2020
Q2 		$1.66M Sell
34,200
-1,100
-3% -$40.1K ﹤0.01% 4902
2020
Q1 		$981K Buy
35,300
+19,500
+123% +$544K ﹤0.01% 5368
2019
Q4 		$473K Sell
15,800
-9,500
-38% -$273K ﹤0.01% 6904
2019
Q3 		$782K Buy
+25,300
New +$1.03M ﹤0.01% 6013

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ken Griffin's ADPT Position: Q1 2026 in Review

Ken Griffin increased its Adaptive Biotechnologies (ADPT) stake by 538% in Q1 2026, buying an estimated $4.88M and bringing the position to 363,333 shares worth $5.04M. The position accounts for ﹤0.01% of the portfolio, ranked #4321.

Ken Griffin first reported a position in ADPT in Q2 2019 and has held it in 28 quarters since. The position peaked at $14.4M in Q1 2021. 297 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Ken Griffin held 363,333 shares of Adaptive Biotechnologies worth $5.04M as of Q1 2026.
  • Ken Griffin bought 306,381 Adaptive Biotechnologies shares in Q1 2026, an estimated $4.88M.
  • Adaptive Biotechnologies made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4321 holding.
  • Ken Griffin first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 28 quarters since.
  • Ken Griffin's Adaptive Biotechnologies position peaked at $14.4M in Q1 2021.
  • 297 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.